Tenax Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Tenax Therapeutics, Inc. has announced its Annual Meeting of Stockholders will be held on June 2, 2026, to elect directors and ratify auditors.
NASDAQ
DEFA14A: Tenax Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals for Stockholder Vote
Tenax Therapeutics has scheduled its 2025 Annual Meeting for June 11, 2025, and is seeking stockholder votes on several key proposals, including the election of directors and approval of amendments to the company's certificate of incorporation.
NASDAQ
Tenax Therapeutics is holding its annual meeting on June 11, 2025, to vote on director elections, officer exculpation, stockholder action requirements, executive compensation, and auditor ratification.
NASDAQ
Tenax Therapeutics is asking stockholders to approve an amendment to its 2022 Stock Incentive Plan to increase the number of shares authorized for issuance by 7,935,912 shares.
NASDAQ
Tenax Therapeutics has hired Morrow Sodali to assist with proxy solicitation for its upcoming annual meeting on June 7, 2024.
NASDAQ
Tenax Therapeutics has filed a definitive proxy statement with the SEC.
NASDAQ
DEF 14A: Tenax Therapeutics Seeks Stockholder Approval for Increased Share Issuance Under Incentive Plan
Tenax Therapeutics is holding its annual meeting on June 7, 2024, to vote on director elections, an amendment to the stock incentive plan, and ratification of its accounting firm.